WO/2015/125113 METHOD OF CULTURING HIGH CELL DENSITY PBMC'S||WO||27.08.2015|
||PCT/IB2015/051293||DR. REDDY'S LABORATORIES LIMITED||MEHTA, Gaurav Rajendraprasad|
The present invention relates to a method of attaining high cell density PBMCs that are viable for longer duration in culture. In particular the method involves culturing the cells in lymphocyte growth medium comprising recombinant human interleukin-2 and human serum to acquire cells with a density as high as 108 cells/ml. PBMCs thus obtained remains functionally viable for 25 to 30 days in culture and are also found enriched in NK cell content allowing it to be widely used as effector cells, particularly T-cell response assays.
WO/2015/123272 PARENTERAL COMPOSITIONS OF CELECOXIB||WO||20.08.2015|
||PCT/US2015/015379||DR. REDDY'S LABORATORIES LTD.||OKUMU, Franklin|
Parenteral (injectable) celecoxib emulsions and nanoemulsions are disclosed as are their use to treat pain in patients so afflicted. The emulsions are generally oil in water emulsions often comprised of an oil phase including an oil and a lecithin wherein the mean droplet size of the discontinuous oil phase is about 200 nanometers or less.
WO/2015/121784 METHOD FOR DETECTION OF ANTI-RITUXIMAB ANTIBODIES||WO||20.08.2015|
||PCT/IB2015/050949||DR. REDDY'S LABORATORIES LIMITED||LELLA, Ravi Kumar|
This invention is related to a method for detecting anti-rituximab antibodies in a RF positive plasma samples, wherein the method mitigated the interference of RF to a significant level using biotinylated F(ab)2 fragments of rituximab as detecting agent. The method also used a pre-treatment step with acidic buffer containing glycine, prior to subjecting the samples for detection of anti-rituximab antibodies.
WO/2015/107444 IN-VITRO ASSAY FOR THE ASSESSMENT OF POST TRANSLATIONALLY MODIFIED PROTEIN ISOFORMS||WO||23.07.2015|
||PCT/IB2015/050212||DR.REDDYS LABORATORIES LIMITED||MEDISETTY, Rajesh|
The present invention discloses an in-vitro bioassay for distinguishing post translationally modified isoforms of a protein. In particular, the present invention discloses an in-vitro method for distinguishing post translationally modified isoforms of an antibody by C1q based ELISA involving a metal ion chelator.
WO/2015/059679 IMPROVED PROCESS FOR THE PREPARATION OF ELIGLUSTAT||WO||30.04.2015|
||PCT/IB2014/065631||DR. REDDY'S LABORATORIES LIMITED||JAVED, Iqbal|
The present invention provides an improved process for the preparation of eliglustat to salts thereof. Present invention also provides a crystalline eliglustat free base form R1.
WO/2015/044876 MOLECULAR WEIGHT MARKERS FOR PROTECTED POLYPEPTIDES||WO||02.04.2015|
||PCT/IB2014/064797||DR. REDDY'S LABORATORIES LIMITED||KATKAM, Srinivas|
The present invention provides trifluoroacetyl copolymers useful as standard molecular weight markers in the intermediary stage for obtaining glatiramer acetate having desired average molecular weight. The present invention further provides a process for determining the average molecular weight of glatiramer acetate or other copolymers using molecular weight markers of protected polypeptides.
WO/2015/026737 SELECTABLE SINGLE DOSE AUTO-INJECTOR AND METHODS OF MAKING AND USING SAME||WO||26.02.2015|
||PCT/US2014/051531||DR. REDDY'S LABORATORIES, LTD.||KUMAR, Rajesh|
An auto-injector device for administering a liquid pharmaceutical composition, in which an end-user can select between doses that the device is capable of delivering. The end-user choices that translate into the selected doses can be based on end-user perceived severity of symptoms, end-user weight and other such factors. In some embodiments the auto-injector is configured to administer the one chosen dose only. In other embodiments, the auto-injector can deliver second and subsequent doses up to full dose of the pharmaceutical composition disposed in the injector. The auto-injector can provide visual, audio, and tactile feedback, alone or in combination, to the user to indicate the dose selected, instructions for use, and when the dose has been administered.
WO/2014/188353 PROCESSES FOR THE PREPARATION OF DEHYDROEPIANDROSTERONE AND ITS INTERMEDIATES||WO||27.11.2014|
||PCT/IB2014/061590||DR. REDDY'S LABORATORIES LIMITED||FRYSZKOWSKA, Anna|
The present application relates to a regioselective and stereoselective processes for the preparation of dehydroepiandrosterone (DHEA) and processes for its intermediates.
WO/2014/170866 PROCESS OF OBTAINING GLYCOPROTEIN COMPOSITION WITH INCREASED GALACTOSYLATION CONTENT||WO||23.10.2014|
||PCT/IB2014/060812||DR. REDDY'S LABORATORIES LIMITED||THUDUPPATHY, Guruvasuthevan Ramasamy|
A cell culture process for production of glycoprotein composition with increased galactosylation content while maintaining specific productivity is provided. The process involves culturing cells at high pCO 2 and subjecting cells to temperature downshift to obtain a glycoprotein with specific glycoprotein composition.
WO/2014/155349 REFOLDING OF PROTEINS||WO||02.10.2014|
||PCT/IB2014/060251||DR. REDDY'S LABORATORIES||PARAYITAM, Bharata, Ratnam|
Provided is a method of refolding of recombinant GCSF that minimizes the generation of oxidized forms of GCSF by optimizing the refolding of inclusion bodies containing recombinant GCSF.